Everolimus 0.25 mg Tablet PCD Franchise, Immunosuppressant Tablet Supplier India, Everolimus Tablet Manufacturer, Transplant Rejection Medicine Distributor, Best Price Pharma Franchise

Everolimus Tablet Franchise in Ahmedabad

Immunosuppressant Tablet Distributor in Delhi

Everolimus Tablet Manufacturer in Bangalore

Transplant Medicine Tablet Stockist in Hyderabad
Everolimus Tablet Exporter in Chandigarh

Home/Products /everolimus-0-25mg-tablet

Everloop 0.25 Tablet

Composition : Everolimus (0.25mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹0/-

Please Contact For Best Price

Everloop 0.25 Tablet contains Everolimus 0.25 mg, an mTOR inhibitor with potent immunosuppressive and antiproliferative properties. It is widely used in organ transplant patients to prevent rejection and in selected oncology indications where controlled inhibition of cell growth is required.

Everolimus works by blocking the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and reducing abnormal cell proliferation. This mechanism helps in maintaining graft survival while minimizing immune-mediated damage.

Clinically, Everloop 0.25 Tablet is prescribed for post-transplant immunosuppression and specific tumor-related therapies, often as part of combination treatment protocols under strict medical supervision.

The tablet offers precise low-dose control, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital use, transplant centers, and specialized clinical settings requiring long-term immune modulation.

Read More

About the Product

Everloop 0.25 Tablet contains Everolimus 0.25 mg, an mTOR inhibitor with potent immunosuppressive and antiproliferative properties. It is widely used in organ transplant patients to prevent rejection and in selected oncology indications where controlled inhibition of cell growth is required.

Everolimus works by blocking the mammalian target of rapamycin (mTOR) pathway, thereby suppressing T-cell activation and reducing abnormal cell proliferation. This mechanism helps in maintaining graft survival while minimizing immune-mediated damage.

Clinically, Everloop 0.25 Tablet is prescribed for post-transplant immunosuppression and specific tumor-related therapies, often as part of combination treatment protocols under strict medical supervision.

The tablet offers precise low-dose control, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospital use, transplant centers, and specialized clinical settings requiring long-term immune modulation.

Common side effects may include mouth ulcers, infections, fatigue, rash, diarrhea, nausea, and increased blood lipid levels. Rarely, serious effects such as impaired wound healing, lung toxicity, severe infections, or blood count abnormalities may occur.

Everloop 0.25 Tablet is indicated for the prevention of organ transplant rejection in combination with other immunosuppressants. It is also used in the treatment of specific cancers and benign tumors, such as renal cell carcinoma, neuroendocrine tumors, and tuberous sclerosis complex–associated conditions, as prescribed by a specialist.

Use Everloop 0.25 Tablet strictly under specialist supervision. Regular monitoring of blood counts, kidney function, lipid profile, and drug levels may be required. Inform your doctor if you have active infections, liver impairment, or are taking other immunosuppressive medicines. Avoid live vaccines during therapy and seek immediate medical attention if signs of infection or breathing difficulty occur.

Store below 25°C in a dry place. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.

Get in Touch